Effect of eribulin on patients with metastatic breast cancer: multicenter retrospective observational study in Taiwan

Kun Ming Rau, Fu Ou-Yang, Ta Chung Chao, Yao Lung Kuo, Tsui Fen Cheng, Tsu Yi Chao, Dar Ren Chen, Yen Dun Tzeng, Being Whey Wang, Chun Yu Liu, Ming Hung Hu, Yin Che Lu, Wei Jen Ou, Chin Ho Kuo, Chieh Han Chuang, Jung Yu Kan, Fang Ming Chen, Ming Feng Hou

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Purpose: The aim of this study was to confirm the therapeutic role of eribulin on Taiwanese women with metastatic breast cancer. Methods: This retrospective study examined 449 females who received eribulin between March 2014 and June 2017 at 14 hospitals in Taiwan for treatment of locally advanced or metastatic breast cancer. Results: The survival rate at 24 months was 57.2% (95% CI 51.0–62.9%) and the median time to treatment failure (TTF) was 3.91 months (95% CI 3.45–3.94). A total of 175 patients (40.1%) received eribulin for fewer than 90 days and the others received it for 90 days or more. Eight patients (1.83%) had complete remission, 82 (18.8%) had partial remission, 202 (46.3%) had stable disease, and 144 (33.0%) had progressive disease (PD). Patients’ tumors with the luminal A subtype had a significantly better objective response rate. Kaplan–Meier analysis indicated that hormone receptor positivity, luminal A subtype, receipt of eribulin as the 1st to 3rd line therapy, and metastasis to fewer than 4 organs were significantly associated with longer TTF. Stepwise multivariate analysis showed that only receipt of eribulin as the 1st to 3rd line therapy was significantly associated with TTF (HR 1.49, p < 0.001). All toxicities were manageable and only 18 patients (4.1%) discontinued treatment due to adverse events. Conclusions: Eribulin appears to have better efficacy and cause fewer adverse events, especially neutropenia, in Taiwanese women than Western women.

Original languageEnglish
Pages (from-to)1-9
Number of pages9
JournalBreast Cancer Research and Treatment
DOIs
Publication statusAccepted/In press - Apr 5 2018

Keywords

  • Efficacy
  • Eribulin
  • Metastatic breast cancer
  • Real world
  • Safety
  • Taiwanese women

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Effect of eribulin on patients with metastatic breast cancer: multicenter retrospective observational study in Taiwan'. Together they form a unique fingerprint.

  • Cite this

    Rau, K. M., Ou-Yang, F., Chao, T. C., Kuo, Y. L., Cheng, T. F., Chao, T. Y., Chen, D. R., Tzeng, Y. D., Wang, B. W., Liu, C. Y., Hu, M. H., Lu, Y. C., Ou, W. J., Kuo, C. H., Chuang, C. H., Kan, J. Y., Chen, F. M., & Hou, M. F. (Accepted/In press). Effect of eribulin on patients with metastatic breast cancer: multicenter retrospective observational study in Taiwan. Breast Cancer Research and Treatment, 1-9. https://doi.org/10.1007/s10549-018-4778-y